Pms29 - Secukinumab Versus Adalimumab in the Treatment of Ankylosing Spondylitis: A Cost Per Responder Analysis Among 52 Weeks From a Tunisian Perspective.
Value in Health- United Kingdom
doi 10.1016/j.jval.2018.09.1743
Full Text
Abstract
Available in
Date
October 1, 2018
Authors
Publisher
Elsevier BV